Metagenomi, Inc.
MGX
$1.67
$0.159.87%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 9.61M | 11.51M | 20.01M | 11.16M | 12.40M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.61M | 11.51M | 20.01M | 11.16M | 12.40M |
| Cost of Revenue | 23.16M | 26.26M | 28.32M | 31.44M | 24.76M |
| Gross Profit | -13.55M | -14.74M | -8.31M | -20.28M | -12.36M |
| SG&A Expenses | 7.07M | 7.64M | 8.55M | 8.75M | 7.84M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.24M | 33.90M | 36.87M | 40.19M | 32.60M |
| Operating Income | -20.62M | -22.38M | -16.86M | -29.03M | -20.20M |
| Income Before Tax | -24.61M | -20.88M | -12.94M | -25.15M | -16.57M |
| Income Tax Expenses | -1.21M | -2.11M | -2.20M | -- | 2.73M |
| Earnings from Continuing Operations | -23.40M | -18.77M | -10.74M | -25.15M | -19.29M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.40M | -18.77M | -10.74M | -25.15M | -19.29M |
| EBIT | -20.62M | -22.38M | -16.86M | -29.03M | -20.20M |
| EBITDA | -19.16M | -21.02M | -15.55M | -27.76M | -19.00M |
| EPS Basic | -0.63 | -0.51 | -0.29 | -1.19 | -5.67 |
| Normalized Basic EPS | -0.29 | -0.32 | -0.22 | -0.74 | -3.04 |
| EPS Diluted | -0.63 | -0.51 | -0.29 | -1.19 | -5.67 |
| Normalized Diluted EPS | -0.29 | -0.32 | -0.22 | -0.74 | -3.04 |
| Average Basic Shares Outstanding | 37.31M | 36.77M | 36.63M | 21.14M | 3.40M |
| Average Diluted Shares Outstanding | 37.31M | 36.77M | 36.63M | 21.14M | 3.40M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |